Reviewing Dynavax Technologies (NASDAQ:DVAX) and Nabriva Therapeutics (NASDAQ:NBRV)

Dynavax Technologies (NASDAQ:DVAX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Valuation & Earnings

This table compares Dynavax Technologies and Nabriva Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynavax Technologies	$249.69 million	6.03	-$6.39 million	$0.06	191.67
Nabriva Therapeutics	$35.59 million	0.00	-$57.19 million	($19.20)	N/A

Dynavax Technologies has higher revenue and earnings than Nabriva Therapeutics. Nabriva Therapeutics is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dynavax Technologies and Nabriva Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dynavax Technologies	6.88%	2.76%	1.73%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Institutional & Insider Ownership

97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for Dynavax Technologies and Nabriva Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynavax Technologies	0	1	3	0	2.75
Nabriva Therapeutics	0	0	0	0	N/A

Dynavax Technologies currently has a consensus price target of $23.67, indicating a potential upside of 105.80%.

Volatility and Risk

Dynavax Technologies has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.

Summary

Dynavax Technologies beats Nabriva Therapeutics on 10 of the 11 factors compared between the two stocks.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.